Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 5Recruiting 4Active not recruiting 3Terminated 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 112Recurrence 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Neoplasms 14Neoplasms, Plasma Cell 13Leukemia 10Lymphoma, Non-Hodgkin 8Lymphoma 8Leukemia, Myeloid, Acute 8Carcinoma, Non-Small-Cell Lung 8Lymphoma, Large B-Cell, Diffuse 7Burkitt Lymphoma 7Vomiting 6Prostatic Neoplasms 6Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Nausea 5Lung Neoplasms 5Pancreatic Neoplasms 3Lymphoma, Follicular 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Neoplasms 3Hematologic Diseases 3Glioblastoma 3Amyloidosis 3Smoldering Multiple Myeloma 2Renal Insufficiency 2Oligodendroglioma 2Myelodysplastic Syndromes 2

Interventions

Dexamethasone 2Calcium Dobesilate 2Bortezomib 2pomalidomide 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1atezolizumab 1Transplantation, Autologous 1Melphalan 1Lenalidomide 1Gene Expression Profiling 1Fatty Acids, Omega-3 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Smoldering Multiple Myeloma × Dexamethasone × Clear all
NCT05288062 2025-08-20

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Mayo Clinic

Phase 2 Terminated
17 enrolled 9 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT02353572 2015-03-09

Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

University of Colorado, Denver

Phase 1/2 Terminated
3 enrolled 5 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡